共 7 条
[1]
Worm M., Moneret-Vautrin A., Scherer K., Lang R., Fernandez-Rivas M., Cardona V., Et al., First European data from the network of severe allergic reactions (NORA), Allergy, 69, pp. 1397-1404, (2014)
[2]
Przybilla B., Rueff F., Walker A., Rawer H.C., Aberer W., Bauer C.P., Et al., Diagnose und Therapie der Bienen- und Wespengiftallergie, Allergo J, 20, pp. 318-339, (2011)
[3]
Klimek L., Pfaar O., Worm M., Bergmann K.C., Bieber T., Buhl R., Et al., Allergen-Immuntherapie in der Aktuellen Covid-19-Pandemie, Allergo J, 29, 3, pp. 17-25, (2020)
[4]
Shaker M.S., Wallace D.V., Golden D.B.K., Oppenheimer J., Bernstein J.A., Campbell R.L., Et al., Anaphylaxis-a 2020 practice parameter update, systematic review, and grading of recommendations, assessment, development and evaluation (GRADE) analysis, J Allergy Clin Immunol, 145, pp. 1082-1123, (2020)
[5]
Brehler R., Wolf H., Kutting B., Schnitker J., Luger T., Safety of a two-day ultrarush insect venom immunotherapy protocol in comparison with protocols of longer duration and involving a larger number of injections, J Allergy Clin Immunol, 105, pp. 1231-1235, (2000)
[6]
Lee H., Roediger C., Bauer A., Zuberbier T., Worm M., Prospective safety analysis of an ultrarush specific immunotherapy in adults with wasp venom allergy, Allergy, 61, pp. 1237-1238, (2006)
[7]
Schrautzer C., Arzt-Gradwohl L., Bokanovic D., Schwarz I., Cerpes U., Koch L., Et al., A safe and efficient 7-week immunotherapy protocol with aluminum hydroxide adsorbed vespid venom, Allergy, 75, pp. 678-680, (2020)